{"product_id":"retatrutide-24mg","title":"Retatrutide – 24 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — a single molecule that activates the \u003cstrong\u003eGIP\u003c\/strong\u003e, \u003cstrong\u003eGLP-1\u003c\/strong\u003e and \u003cstrong\u003eglucagon\u003c\/strong\u003e receptors at once. The added glucagon arm is thought to raise \u003cstrong\u003eenergy expenditure\u003c\/strong\u003e on top of the appetite reduction driven by GIP and GLP-1\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a 48-week \u003cstrong\u003ePhase 2 obesity trial\u003c\/strong\u003e, participants on the 12 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 24.2%\u003c\/strong\u003e, versus 2.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e83%\u003c\/strong\u003e of that group lost 15% or more of their body weight, and \u003cstrong\u003e93%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIn a separate \u003cstrong\u003ePhase 2 type-2-diabetes trial\u003c\/strong\u003e, retatrutide lowered HbA1c by up to \u003cstrong\u003e2.02 points\u003c\/strong\u003e and cut body weight by about \u003cstrong\u003e16.9%\u003c\/strong\u003e at 36 weeks — outperforming the GLP-1 agonist dulaglutide\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the retatrutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816107557091,"sku":"RT26-A","price":195.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-retatrutide-24-mg.png?v=1784483919","url":"https:\/\/qovigen.com\/products\/retatrutide-24mg","provider":"Qovigen Peptides","version":"1.0","type":"link"}